Insmed, Inc. $INSM Shares Bought by Ethic Inc.

Ethic Inc. lifted its holdings in shares of Insmed, Inc. (NASDAQ:INSM – Free Report) by 109.9% during the 3rd quarter, Holdings Channel.com reports. The firm owned 10,498 shares of the biopharmaceutical company’s stock after acquiring an additional 5,496 shares during the period. Ethic Inc.’s holdings in Insmed were worth $1,198,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Virginia Estate & Retirement Planning Advisors Inc. acquired a new position in Insmed in the third quarter valued at $29,000. SBI Securities Co. Ltd. lifted its position in Insmed by 69.4% during the third quarter. SBI Securities Co. Ltd. now owns 349 shares of the biopharmaceutical company’s stock worth $40,000 after buying an additional 143 shares during the period. CX Institutional acquired a new stake in Insmed in the 3rd quarter worth about $46,000. Harbor Investment Advisory LLC acquired a new stake in Insmed in the 2nd quarter worth about $52,000. Finally, Heritage Family Offices LLP acquired a new stake in Insmed in the 3rd quarter worth about $60,000.

Insmed Stock Performance

Shares of INSM stock opened at $121.16 on Friday. The company’s fifty day simple moving average is $110.82 and its 200-day simple moving average is $123.37. The company has a market cap of $26.58 billion, a PE ratio of -42.96 and a beta of 0.83. Insmed, Inc. has a 52 week low of $90.39 and a 52 week high of $212.75. The company has a current ratio of 2.86, a quick ratio of 2.59 and a debt-to-equity ratio of 0.77.

Insmed (NASDAQ:INSM – Get Free Report) last posted its earnings results on Thursday, October 29th. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.08). Insmed had a negative net margin of 39.85% and a negative return on equity of 96.38%. The company had revenue of $524.43 million during the quarter, compared to analyst estimates of $500.36 million. During the same quarter last year, the business posted ($1.75) EPS. Insmed’s quarterly revenue was up 268.4% compared to the same quarter last year. As a group, equities research analysts anticipate that Insmed, Inc. will post -1.86 EPS for the current year.

Wall Street Analyst Weigh In

INSM has been the subject of several recent analyst reports. Morgan Stanley lowered their price target on Insmed from $218.00 to $213.00 and set an “overweight” rating for the company in a report on Wednesday, October 21st. Mizuho set a $154.00 price objective on shares of Insmed in a report on Thursday, October 29th. BMO Capital Markets reissued an “outperform” rating on shares of Insmed in a research report on Tuesday, October 6th. Guggenheim lowered their target price on shares of Insmed from $205.00 to $201.00 and set a “buy” rating for the company in a report on Monday, November 2nd. Finally, HC Wainwright assumed coverage on shares of Insmed in a research report on Wednesday, November 4th. They set a “buy” rating and a $220.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $196.52.

Check Out Our Latest Stock Analysis on INSM

Insider Buying and Selling

In other Insmed news, Director David Brennan sold 25,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 9th. The stock was sold at an average price of $124.00, for a total value of $3,100,000.00. Following the completion of the transaction, the director owned 39,238 shares in the company, valued at $4,865,512. This represents a 38.92% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 2.10% of the company’s stock.

Insmed Profile

(Free Report)

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing treatments for serious diseases, including respiratory and rare conditions. The company is based in Bridgewater, New Jersey, and is led by President and Chief Executive Officer William H. Lewis Jr. Its commercial products include ARIKAYCE, an inhaled amikacin treatment for certain adults with refractory Mycobacterium avium complex lung disease, and BRINSUPRI (brensocatib), an oral treatment for non-cystic fibrosis bronchiectasis.

Further Reading

Want to see what other hedge funds are holding INSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insmed, Inc. (NASDAQ:INSM – Free Report).

Institutional Ownership by Quarter for Insmed (NASDAQ:INSM)

Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.